MARKET

SGEN

SGEN

Seattle Genetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

70.63
-0.25
-0.35%
After Hours: 70.63 0 0.00% 16:32 09/13 EDT
OPEN
70.68
PREV CLOSE
70.88
HIGH
71.68
LOW
70.24
VOLUME
647.08K
TURNOVER
--
52 WEEK HIGH
84.37
52 WEEK LOW
50.71
MARKET CAP
11.92B
P/E (TTM)
-40.4780
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SGEN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 17 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SGEN News

  • Oppenheimer Turns Bullish On Seattle Genetics, Says Optimism Fueled By Pipeline Readouts
  • Benzinga.2d ago
  • Oppenheimer Turns Bullish On Seattle Genetics, Says Optimism Fueled By Pipeline Readouts
  • Benzinga.2d ago
  • UPDATE: Oppenheimer On Seattle Genetics Notes 'two upcoming near-term readouts could deliver value:'
  • Benzinga.2d ago
  • UPDATE: Oppenheimer Upgrades Seattle Genetics To Outperform, Raises Target To $82 Based On Firm's Review 'of two pipeline assets (Enfortumab Vedotin and tucatinib) that focus on less competitive later lines of treatment with strong data'
  • Benzinga.2d ago

More

Industry

Biotechnology & Medical Research
+0.20%
Pharmaceuticals & Medical Research
-0.38%

Hot Stocks

Name
Price
%Change

About SGEN

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company's pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.
More

Webull offers Seattle Genetics, Inc. (SGEN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.